An agent-based model of Epstein-Barr virus transmission and vaccination

Epstein- Barr virus (EBV) infects over 90\% of adults worldwide, causing infectious mononucleosis (IM) in adolescents and young adults and contributing to multiple malignancies. Despite its global burden, population- level transmission modeling of EBV remains limited. We present the first population- level agent-based model (ABM) of EBV transmission. The model is implemented with 10,000 agents and calibrated to age-specific seroprevalence data from the US National Health and Nutrition Examination Survey. Two complementary calibration methods are evaluated, each with its own distinct advantages: Approximate Bayesian Computation (ABC) and Bayesian Optimization with Expected Quantile Improvement (BO- EQI). ABC directly yields an approximate distribution of transmission parameters for propagation through vaccination scenarios. BO- EQI uses a limited simulation budget to identify well-fitting parameter vectors, particularly as the number of fitted parameters increases. We estimate parameter uncertainty at each resolution in a separate Gaussian-kernel posterior analysis, which requires additional simulations and an explicit model for discrepancies between simulated and observed prevalence. As an illustrative application, we simulate the population-level effect of hypothetical EBV vaccines over a 100-year projection horizon. Similar to a previous modeling study, our results suggest that vaccine durability is at least as critical as efficacy, and that a vaccine with direct protection against only EBV may persistently shift IM burden to older ages, an effect our longer simulation horizon reveals to be a durable equilibrium shift rather than a transient cohort phenomenon. These findings highlight the importance of careful vaccine target product profile design; in particular, our results suggest that dual efficacy against both EBV infection and IM progression represents the most promising achievable target profile, and should be a core design objective for next-generation EBV vaccines.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-12
DOI
https://doi.org/10.64898/2026.11.10.26367734
Primary Topic
Viral-associated cancers and disorders
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

An agent-based model of Epstein-Barr virus transmission and vaccination

Zhongda Huang, Edward Wolfgang Thommes, Monica Gabriela Cojocaru, Bridgette Amoako et al.
medRxiv
Viral-associated cancers and disorders
preprint

An agent-based model of Epstein-Barr virus transmission and vaccination

Zhongda Huang, Edward Wolfgang Thommes, Monica Gabriela Cojocaru, Bridgette Amoako, Warren Hare
preprint en

Abstract

Epstein- Barr virus (EBV) infects over 90\% of adults worldwide, causing infectious mononucleosis (IM) in adolescents and young adults and contributing to multiple malignancies. Despite its global burden, population- level transmission modeling of EBV remains limited. We present the first population- level agent-based model (ABM) of EBV transmission. The model is implemented with 10,000 agents and calibrated to age-specific seroprevalence data from the US National Health and Nutrition Examination Survey. Two complementary calibration methods are evaluated, each with its own distinct advantages: Approximate Bayesian Computation (ABC) and Bayesian Optimization with Expected Quantile Improvement (BO- EQI). ABC directly yields an approximate distribution of transmission parameters for propagation through vaccination scenarios. BO- EQI uses a limited simulation budget to identify well-fitting parameter vectors, particularly as the number of fitted parameters increases. We estimate parameter uncertainty at each resolution in a separate Gaussian-kernel posterior analysis, which requires additional simulations and an explicit model for discrepancies between simulated and observed prevalence. As an illustrative application, we simulate the population-level effect of hypothetical EBV vaccines over a 100-year projection horizon. Similar to a previous modeling study, our results suggest that vaccine durability is at least as critical as efficacy, and that a vaccine with direct protection against only EBV may persistently shift IM burden to older ages, an effect our longer simulation horizon reveals to be a durable equilibrium shift rather than a transient cohort phenomenon. These findings highlight the importance of careful vaccine target product profile design; in particular, our results suggest that dual efficacy against both EBV infection and IM progression represents the most promising achievable target profile, and should be a core design objective for next-generation EBV vaccines.

medRxiv
University of British Columbia (CA), University of Guelph (CA)
Good health and well-being
Viral-associated cancers and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon